Enlivex Therapeutics Ltd (ENLV)

$1.15 +0.11 (10.58%)
Market Cap 239.76M
Revenue (ttm) 0.00
Net Income (ttm) -15.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 855,299
Avg Vol 487,302
Day's Range N/A - N/A
Shares Out 237.38M
Stochastic %K 21%
Beta 1.63
Analysts Sell
Price Target $13.00

Company Profile

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis pat...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 2 620 8072
Address:
14 Einstein Street, Ness Ziona, Israel
mbelect
mbelect Jun. 30 at 9:04 PM
$ENLV 10 years of wasting money where are the results? its been the lenght of a generation a decade. what kinda bullshit bio company is this? what to expect as an investor? when will we see our return, when we die!!!!????
1 · Reply
patk007
patk007 Jun. 30 at 3:32 PM
$ENLV 625 bio blast sitting in my account .. Cant trade that? Anyone has an update?
1 · Reply
Pacho_Unlimited1
Pacho_Unlimited1 Jun. 25 at 2:32 PM
$ENLV ....strange thing: I got a message from my broker about the R/S, but it's not as yet announced on the website of ENLV.
2 · Reply
Pacho_Unlimited1
Pacho_Unlimited1 Jun. 25 at 2:25 PM
$ENLV Reverse Split!!!!!!
1 · Reply
mbelect
mbelect Jun. 24 at 11:39 AM
$ENLV where did our money go? now im 95% negative. did they invest our money in RAIN and now we wont even get profit out of that? what kind a scam are they running here from $20/share in 2021 to $.58 is anyone still believing in this company?
3 · Reply
GolfAndStockzz
GolfAndStockzz Jun. 22 at 5:03 PM
$ENLV guess i need another 5k shares to round out the bag to 20k
0 · Reply
churchman42
churchman42 Jun. 22 at 3:20 PM
$ENLV
1 · Reply
focafoca99
focafoca99 Jun. 22 at 1:17 PM
$ENLV released an update on its RAIN token holdings.
0 · Reply
2sexyBiatch
2sexyBiatch Jun. 22 at 1:08 PM
$ENLV wack this dead
0 · Reply
SPARTANVI
SPARTANVI Jun. 22 at 12:47 PM
$WNW known runner looks primed again for a major move High ctb 470k float Adding $ENLV $NXTS
0 · Reply
Latest News on ENLV
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume

Jun 24, 2026, 8:00 AM EDT - 10 days ago

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion

Jun 22, 2026, 8:45 AM EDT - 12 days ago

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion

Enlivex Therapeutics announces issuance of Australian patent

2026-06-15T13:01:02.000Z - 19 days ago

Enlivex Therapeutics announces issuance of Australian patent

Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis

Jun 15, 2026, 8:00 AM EDT - 19 days ago

Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis

ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026

Jun 2, 2026, 8:00 AM EDT - 4 weeks ago

ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026

Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026

Jun 1, 2026, 8:00 AM EDT - 4 weeks ago

Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board

May 28, 2026, 8:00 AM EDT - 5 weeks ago

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board

Enlivex comments on $100M commitment to Rain’s prediction market

2026-05-27T15:37:44.000Z - 5 weeks ago

Enlivex comments on $100M commitment to Rain’s prediction market

Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity

May 27, 2026, 8:00 AM EDT - 5 weeks ago

Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity

Enlivex Therapeutics doses first patient in Allocetra trial

2026-05-18T12:17:18.000Z - 6 weeks ago

Enlivex Therapeutics doses first patient in Allocetra trial

Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

May 18, 2026, 8:00 AM EDT - 6 weeks ago

Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification

May 15, 2026, 4:10 PM EDT - 7 weeks ago

Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange

Apr 30, 2026, 8:30 AM EDT - 2 months ago

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange

Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million

Apr 28, 2026, 8:30 AM EDT - 2 months ago

Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million

Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress

Apr 23, 2026, 8:30 AM EDT - 2 months ago

Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress

Enlivex Therapeutics files to sell 23.33M ordinary shares for holders

2026-04-21T20:54:59.000Z - 2 months ago

Enlivex Therapeutics files to sell 23.33M ordinary shares for holders

Enlivex receives CTA approval by DKMA for Phase 2b trial of Allocetra

2026-04-21T12:58:15.000Z - 2 months ago

Enlivex receives CTA approval by DKMA for Phase 2b trial of Allocetra

Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Apr 21, 2026, 8:30 AM EDT - 2 months ago

Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Enlivex Registration statement: Registration filing

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Enlivex Registration statement: Registration filing

Ondo Global Markets Tokenizes Enlivex's Ordinary Shares

Apr 8, 2026, 8:30 AM EDT - 3 months ago

Ondo Global Markets Tokenizes Enlivex's Ordinary Shares

Enlivex Therapeutics price target raised to $20 from $13 at H.C. Wainwright

2026-04-07T10:07:47.000Z - 3 months ago

Enlivex Therapeutics price target raised to $20 from $13 at H.C. Wainwright

Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt

Mar 26, 2026, 8:30 AM EDT - 3 months ago

Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt

Enlivex Earnings Call Transcript: Q4 2025

Mar 25, 2026, 9:00 AM EDT - 3 months ago

Enlivex Earnings Call Transcript: Q4 2025

Enlivex Annual report: Q4 2025

Mar 25, 2026, 9:00 AM EDT - 3 months ago

Enlivex Annual report: Q4 2025

Enlivex Quarterly report: Q4 2025

Mar 25, 2026, 9:00 AM EDT - 3 months ago

Enlivex Quarterly report: Q4 2025

Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48

Mar 25, 2026, 8:30 AM EDT - 3 months ago

Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48

Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program

Mar 24, 2026, 8:30 AM EDT - 3 months ago

Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program

Enlivex Slides: Investor presentation

Mar 24, 2026, 8:00 AM EDT - 3 months ago

Enlivex Slides: Investor presentation

Enlivex Therapeutics announces FDA clearance of Allocetra new drug application

2026-03-23T12:21:45.000Z - 3 months ago

Enlivex Therapeutics announces FDA clearance of Allocetra new drug application

Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Mar 23, 2026, 8:00 AM EDT - 3 months ago

Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Enlivex Therapeutics management to meet virtually with BTIG

2026-02-18T17:40:32.000Z - 4 months ago

Enlivex Therapeutics management to meet virtually with BTIG

Enlivex Therapeutics announces new listing of RAIN token on Kraken

2026-02-10T13:11:38.000Z - 5 months ago

Enlivex Therapeutics announces new listing of RAIN token on Kraken

Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange

Feb 10, 2026, 8:00 AM EST - 5 months ago

Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange

Enlivex Therapeutics announces listing of RAIN token on WhiteBIT

2026-01-26T13:11:08.000Z - 5 months ago

Enlivex Therapeutics announces listing of RAIN token on WhiteBIT

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange

Jan 26, 2026, 8:00 AM EST - 5 months ago

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange

Enlivex Therapeutics shares to trade exclusively on Nasdaq

2026-01-23T13:05:21.000Z - 5 months ago

Enlivex Therapeutics shares to trade exclusively on Nasdaq

Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq

Jan 23, 2026, 8:00 AM EST - 5 months ago

Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq

Enlivex Therapeutics price target raised to $13 from $7 at H.C. Wainwright

2026-01-12T11:10:08.000Z - 6 months ago

Enlivex Therapeutics price target raised to $13 from $7 at H.C. Wainwright

Enlivex says RAIN token listed on KuCoin crypto exchange

2026-01-07T13:28:01.000Z - 6 months ago

Enlivex says RAIN token listed on KuCoin crypto exchange

Enlivex Therapeutics files to sell 212M ordinary shares for holders

2025-12-23T21:40:13.000Z - 6 months ago

Enlivex Therapeutics files to sell 212M ordinary shares for holders

Enlivex Registration statement: Registration Filing

Dec 23, 2025, 7:00 AM EST - 6 months ago

Enlivex Registration statement: Registration Filing

Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development

Dec 4, 2025, 8:00 AM EST - 7 months ago

Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development

Enlivex Therapeutics closes $212M private placement

2025-11-26T13:10:18.000Z - 7 months ago

Enlivex Therapeutics closes $212M private placement

Enlivex Therapeutics downgraded to Hold from Buy at D. Boral Capital

2025-11-24T15:45:17.000Z - 7 months ago

Enlivex Therapeutics downgraded to Hold from Buy at D. Boral Capital

Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors

Nov 24, 2025, 10:00 AM EST - 7 months ago

Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors

Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

Nov 24, 2025, 7:55 AM EST - 7 months ago

Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

Nov 24, 2025, 6:40 AM EST - 7 months ago

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 8 months ago

Enlivex Quarterly report: Q3 2025

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

Oct 28, 2025, 8:15 AM EDT - 8 months ago

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

Sep 29, 2025, 8:15 AM EDT - 9 months ago

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

Sep 11, 2025, 8:00 AM EDT - 10 months ago

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Sep 9, 2025, 8:00 AM EDT - 10 months ago

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Enlivex Quarterly report: Q2 2025

Aug 29, 2025, 4:00 PM EDT - 11 months ago

Enlivex Quarterly report: Q2 2025

Enlivex Transcript: Status Update

Aug 18, 2025, 8:00 AM EDT - 11 months ago

Enlivex Transcript: Status Update

Enlivex Press release: Status Update

Aug 18, 2025, 8:00 AM EDT - 11 months ago

Enlivex Press release: Status Update

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

Aug 18, 2025, 7:45 AM EDT - 11 months ago

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

Aug 14, 2025, 8:30 AM EDT - 11 months ago

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

Jul 28, 2025, 8:30 AM EDT - 1 year ago

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

Jun 10, 2025, 8:30 AM EDT - 1 year ago

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

Enlivex Slides: Company Presentation

Jun 3, 2025, 6:00 PM EDT - 1 year ago

Enlivex Slides: Company Presentation

Enlivex Earnings release: Q1 2025

May 29, 2025, 6:00 PM EDT - 1 year ago

Enlivex Earnings release: Q1 2025

Enlivex Selected to Present at Israeli BioMed 2025 Conference

May 20, 2025, 8:00 AM EDT - 1 year ago

Enlivex Selected to Present at Israeli BioMed 2025 Conference

Enlivex Registration statement: Registration Filing

May 2, 2025, 8:00 AM EDT - 1 year ago

Enlivex Registration statement: Registration Filing

Enlivex Annual report: Q4 2024

Apr 29, 2025, 6:00 PM EDT - 1 year ago

Enlivex Annual report: Q4 2024

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Apr 23, 2025, 8:30 AM EDT - 1 year ago

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Apr 21, 2025, 8:30 AM EDT - 1 year ago

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Enlivex Slides: Company Presentation

Mar 6, 2025, 7:00 AM EST - 1 year ago

Enlivex Slides: Company Presentation

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

Mar 4, 2025, 4:30 PM EST - 1 year ago

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Mar 3, 2025, 8:22 AM EST - 1 year ago

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

Feb 18, 2025, 6:20 AM EST - 1 year ago

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jan 10, 2025, 9:00 AM EST - 1 year ago

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Dec 11, 2024, 8:30 AM EST - 1 year ago

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Dec 5, 2024, 10:49 AM EST - 1 year ago

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Quarterly report: Q3 2024

Nov 28, 2024, 6:00 PM EST - 1 year ago

Enlivex Quarterly report: Q3 2024

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

Nov 26, 2024, 10:15 AM EST - 1 year ago

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Nov 14, 2024, 8:00 AM EST - 1 year ago

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Sep 24, 2024, 8:30 AM EDT - 1 year ago

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 30, 2024, 9:00 AM EDT - 2 years ago

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GP

Enlivex Quarterly report: Q2 2024

Aug 29, 2024, 6:00 PM EDT - 2 years ago

Enlivex Quarterly report: Q2 2024

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jul 19, 2024, 9:00 AM EDT - 2 years ago

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

mbelect
mbelect Jun. 30 at 9:04 PM
$ENLV 10 years of wasting money where are the results? its been the lenght of a generation a decade. what kinda bullshit bio company is this? what to expect as an investor? when will we see our return, when we die!!!!????
1 · Reply
patk007
patk007 Jun. 30 at 3:32 PM
$ENLV 625 bio blast sitting in my account .. Cant trade that? Anyone has an update?
1 · Reply
Pacho_Unlimited1
Pacho_Unlimited1 Jun. 25 at 2:32 PM
$ENLV ....strange thing: I got a message from my broker about the R/S, but it's not as yet announced on the website of ENLV.
2 · Reply
Pacho_Unlimited1
Pacho_Unlimited1 Jun. 25 at 2:25 PM
$ENLV Reverse Split!!!!!!
1 · Reply
mbelect
mbelect Jun. 24 at 11:39 AM
$ENLV where did our money go? now im 95% negative. did they invest our money in RAIN and now we wont even get profit out of that? what kind a scam are they running here from $20/share in 2021 to $.58 is anyone still believing in this company?
3 · Reply
GolfAndStockzz
GolfAndStockzz Jun. 22 at 5:03 PM
$ENLV guess i need another 5k shares to round out the bag to 20k
0 · Reply
churchman42
churchman42 Jun. 22 at 3:20 PM
$ENLV
1 · Reply
focafoca99
focafoca99 Jun. 22 at 1:17 PM
$ENLV released an update on its RAIN token holdings.
0 · Reply
2sexyBiatch
2sexyBiatch Jun. 22 at 1:08 PM
$ENLV wack this dead
0 · Reply
SPARTANVI
SPARTANVI Jun. 22 at 12:47 PM
$WNW known runner looks primed again for a major move High ctb 470k float Adding $ENLV $NXTS
0 · Reply
Stock_Catcher
Stock_Catcher Jun. 22 at 12:46 PM
$ENLV Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
0 · Reply
peacewealth7447
peacewealth7447 Jun. 21 at 12:50 PM
$ENLV Anyone know when Rain Prediction will have a mobile app? When will any of the rain platforms have a mobile app?
1 · Reply
dirk805
dirk805 Jun. 18 at 1:06 PM
$ENLV i also added another 1k
0 · Reply
Nicks_pics
Nicks_pics Jun. 15 at 4:40 PM
$ENLV Added 1k @.66
2 · Reply
FST3
FST3 Jun. 10 at 7:48 PM
$ENLV - Currently the SP of 0.665 per share is basically valuing the Rain Tokens at $0.002 per token, 5 times below the current value. Basically todays value suggests that the Rain tokens are worth below what the ENLV option is. Are shorts suggesting that the Phase I/II results from the trial are also worthless? Help me understand this?
2 · Reply
churchman42
churchman42 Jun. 10 at 6:04 PM
$ENLV
0 · Reply
Burg44
Burg44 Jun. 5 at 9:17 AM
$ENLV because they have over $1.X Billion in RAIN tokens and there market cap is < $200 Mil. Thats 5x under valued !
0 · Reply
GolfAndStockzz
GolfAndStockzz Jun. 5 at 3:18 AM
$ENLV 5 yr hold 🔒
0 · Reply
cled
cled Jun. 5 at 2:34 AM
$ENLV
0 · Reply
dirk805
dirk805 Jun. 3 at 4:44 AM
$ENLV i forgot a green slap
0 · Reply
dirk805
dirk805 Jun. 3 at 4:43 AM
$ENLV yeah, im gonna hop in tomorrow for a long hold. Maybe some 2.5 nov's too. 30 bucks with 6k OI.
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jun. 2 at 2:30 PM
$ENLV
0 · Reply